Cargando…

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells

BACKGROUNDS: Approximately 1,000 microRNAs (miRs) are present in the human genome; however, little is known about the regulation of miR transcription. Because miR levels are deregulated in chronic lymphocytic leukemia (CLL) and signal transducer and activator of transcription (STAT)-3 is constitutiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rozovski, Uri, Calin, George A, Setoyama, Tetsuro, D’Abundo, Lucilla, Harris, David M, Li, Ping, Liu, Zhiming, Grgurevic, Srdana, Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan A, O’Brien, Susan, Wierda, William G, Keating, Michael J, Estrov, Zeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671957/ https://www.ncbi.nlm.nih.gov/pubmed/23725032 http://dx.doi.org/10.1186/1476-4598-12-50

Ejemplares similares

Signal Transducer and Activator of Transcription–3 Induces MicroRNA-155 Expression in Chronic Lymphocytic Leukemia
por: Li, Ping, et al.
Publicado: (2013)

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2018)

STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2018)

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2021)

Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial
por: Jain, Preetesh, et al.
Publicado: (2017)

Stat3 Activates the Receptor Tyrosine Kinase Like Orphan Receptor-1 Gene in Chronic Lymphocytic Leukemia Cells
por: Li, Ping, et al.
Publicado: (2010)

Interleukin-7 receptor-α gene mutations are not detected in adult T-cell acute lymphoblastic leukemia
por: Rozovski, Uri, et al.
Publicado: (2014)

Epstein–Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival()
por: Ferrajoli, Alessandra, et al.
Publicado: (2015)

The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment
por: Kim, Ekaterina, et al.
Publicado: (2019)

The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide
por: Shaim, Hila, et al.
Publicado: (2018)

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
por: Thompson, Philip A., et al.
Publicado: (2018)

The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
por: Fiorcari, Stefania, et al.
Publicado: (2013)

Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma
por: Moshiri, Farzaneh, et al.
Publicado: (2014)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
por: Al-Kali, Aref, et al.
Publicado: (2010)

P637: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL
por: Burger, Jan, et al.
Publicado: (2023)

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
por: Jain, Nitin, et al.
Publicado: (2016)

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models
por: Callegari, Elisa, et al.
Publicado: (2022)

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models
por: Callegari, Elisa, et al.
Publicado: (2022)

PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.
por: Burger, J., et al.
Publicado: (2022)

A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia
por: Schweighofer, Carmen D., et al.
Publicado: (2011)

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eμ-TCL1 mouse model
por: Bresin, Antonella, et al.
Publicado: (2015)

TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
por: Bresin, A, et al.
Publicado: (2016)

How Infant and Toddlers’ Media Use Is Related to Sleeping Habits in Everyday Life in Italy
por: Bellagamba, Francesca, et al.
Publicado: (2021)

Understanding organizational perspectives from clinical research stakeholders involved in recruitment for biopharmaceutical-sponsored clinical trials in the United States: Recommendations for organizational initiatives to improve access and inclusivity in clinical research
por: Johnson, Rebecca R., et al.
Publicado: (2023)

miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression
por: Ferracin, Manuela, et al.
Publicado: (2013)

Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine
por: Badar, Talha, et al.
Publicado: (2015)

Signal Transducers and Activators of Transcription (STAT) Family Members in Helminth Infections
por: Becerra-Díaz, Mireya, et al.
Publicado: (2011)

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors
por: Zulbaran‐Rojas, Alejandro, et al.
Publicado: (2018)

miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs
por: Lupini, Laura, et al.
Publicado: (2013)

Barriers and Facilitators of Smoking Cessation among Latinos Living with HIV: Perspectives from Key Leaders of Community-Based Organizations and Clinics
por: Cartujano-Barrera, Francisco, et al.
Publicado: (2021)

Abstract words processing induces parasympathetic activation: A thermal imaging study
por: Paoletti, Melania, et al.
Publicado: (2022)

Analysis of Radiation Toxicity in Mammalian Cells Stably Transduced with Mitochondrial Stat3
por: Zanin, Alisa, et al.
Publicado: (2023)

A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis
por: Jain, Preetesh, et al.
Publicado: (2017)

Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus
por: Callegari, Elisa, et al.
Publicado: (2013)

Pivotal Role of Signal Transducer and Activator of Transcription (Stat)4 and Stat6 in the Innate Immune Response during Sepsis
por: Matsukawa, Akihiro, et al.
Publicado: (2001)

The signal transducers Stat1 and Stat3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia
por: Przanowski, Piotr, et al.
Publicado: (2013)

Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer
por: Pinz, Sophia, et al.
Publicado: (2016)

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication
por: Loh, Chin-Yap, et al.
Publicado: (2019)

Functional analysis of Rousettus aegyptiacus “signal transducer and activator of transcription 1” (STAT1)
por: Fujii, Hikaru, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_s0ka1511akt4k9jfjujjom5e1l